DRUG DEVELOPMENT FOR TOXOPLASMOSIS ASSOCIATED WITH AIDS

发展治疗学分支，基础研究与发展 艾滋病司的一项使命是促进研究 与发现和开发新疗法有关的努力 艾滋病毒感染和机会性感染的治疗 与艾滋病有关。在美国，10%到40%的艾滋病患者 国家有发展弓形虫脑炎（TE）的风险， 潜伏的弓形虫感染的重新激活。 TE的当前疗法 已经被证明是有毒的、昂贵的，或者只是部分有效的。发展 新的，更有效的治疗剂是至关重要的，但它 受到以下限制：l）潜在的临床前试验的难度 2）制药行业普遍缺乏研究， （3）缺乏这方面的信息; 生物和免疫过程，控制慢性和潜在的 弓形虫感染。 这一合同将为迅速进行评价提供关键资源 弓形虫脑炎的新疗法， 弓形体脑炎体内和体外模型的建立 潜伏感染。该项目将补充联合国系统内的其他活动。 该部门通过以下方式促进OI药物发现和开发的战略： 为TE提供体内和体外测试系统， 提供给科学界。 这样的资源将允许NIAID 为制药商发起的药物发现提供关键支持， 鼓励私营机构赞助新药， 药物和药物组合的比较研究，以用于多个 OI预防研究，并为 临床研究设计。

The Developmental Therapeutics Branch, Basic Research and Development Program, Division of AIDS, as part of its mission, facilitates research efforts related to the discovery and development of new therapies for the treatment of HIV infection and the opportunistic infections (OIs) associated with AIDS. Between 10 and 40 % of AIDS patients in the United States are at risk of developing toxoplasmic encephalitis (TE) through reactivation of latent Toxoplasma infections. Current therapies for TE have proven toxic, expensive, or only partially effective. Development of new, more efficacious therapeutic agents is of utmost importance, yet it has been limited by l) the difficulty of preclinical testing of potential therapies 2) the general lack of pharmaceutical industry research and development in this area, and 3) the relative lack of information on the biological and immunologic processes that control chronic and latent Toxoplasma infections. This contract will provide a critical resource for expeditious evaluations of new therapies for toxoplasmic encephalitis and the continued development of in vivo and in vitro models for toxoplasmic encephalitis and latent infection. This project will complement other activities in the Division's strategy to stimulate OI drug discovery and development by providing in vivo and in vitro test systems for TE that are not readily available to the scientific community. Such a resource will allow NIAID to provide critical support for investigator-initiated drug discovery for TE, to stimulate private sector sponsorship of new drugs, to perform comparative studies of drugs and drug combinations to be used in multiple OI prophylaxis studies, and contribute essential information for the design of clinical studies.